Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries.
dc.contributor.author | Stolbrink, M | |
dc.contributor.author | Chinouya, MJ | |
dc.contributor.author | Jayasooriya, S | |
dc.contributor.author | Nightingale, R | |
dc.contributor.author | Evans-Hill, L | |
dc.contributor.author | Allan, K | |
dc.contributor.author | Allen, H | |
dc.contributor.author | Balen, J | |
dc.contributor.author | Beacon, T | |
dc.contributor.author | Bissell, K | |
dc.contributor.author | Chakaya, J | |
dc.contributor.author | Chiang, C-Y | |
dc.contributor.author | Cohen, M | |
dc.contributor.author | Devereux, G | |
dc.contributor.author | El Sony, A | |
dc.contributor.author | Halpin, DMG | |
dc.contributor.author | Hurst, JR | |
dc.contributor.author | Kiprop, C | |
dc.contributor.author | Lawson, A | |
dc.contributor.author | Macé, C | |
dc.contributor.author | Makhanu, A | |
dc.contributor.author | Makokha, P | |
dc.contributor.author | Masekela, R | |
dc.contributor.author | Meme, H | |
dc.contributor.author | Khoo, EM | |
dc.contributor.author | Nantanda, R | |
dc.contributor.author | Pasternak, S | |
dc.contributor.author | Perrin, C | |
dc.contributor.author | Reddel, H | |
dc.contributor.author | Rylance, S | |
dc.contributor.author | Schweikert, P | |
dc.contributor.author | Were, C | |
dc.contributor.author | Williams, S | |
dc.contributor.author | Winders, T | |
dc.contributor.author | Yorgancioglu, A | |
dc.contributor.author | Marks, GB | |
dc.contributor.author | Mortimer, K | |
dc.date.accessioned | 2023-06-20T14:40:16Z | |
dc.date.issued | 2022-11-01 | |
dc.date.updated | 2023-06-20T08:47:11Z | |
dc.description.abstract | BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022.METHODS: Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis.RESULTS: A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution.CONCLUSION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder, collaborative efforts. | en_GB |
dc.description.sponsorship | Wellcome Trust | en_GB |
dc.description.sponsorship | National Institute for Health Research (NIHR) | en_GB |
dc.description.sponsorship | Liverpool School of Tropical Medicine | en_GB |
dc.format.extent | 1023-1032 | |
dc.identifier.citation | Vol. 26, No. 11, pp. 1023-1032 | en_GB |
dc.identifier.doi | https://doi.org/10.5588/ijtld.22.0270 | |
dc.identifier.grantnumber | 203919/Z/16/Z | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/133439 | |
dc.identifier | ORCID: 0000-0003-2009-4406 (Halpin, DMG) | |
dc.language.iso | en | en_GB |
dc.publisher | International Union Against Tuberculosis and Lung Disease | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/36281039 | en_GB |
dc.rights | © 2022 The Union. This article is Open Access under the terms of the Creative Commons CC BY licence. | en_GB |
dc.subject | asthma | en_GB |
dc.subject | COPD | en_GB |
dc.subject | non-communicable disease | en_GB |
dc.subject | chronic respiratory disease | en_GB |
dc.subject | inhalers | en_GB |
dc.subject | essential medicines | en_GB |
dc.title | Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2023-06-20T14:40:16Z | |
dc.identifier.issn | 1027-3719 | |
exeter.place-of-publication | France | |
dc.description | This is the final version. Available from the International Union Against Tuberculosis and Lung Disease via the DOI in this record. | en_GB |
dc.identifier.eissn | 1815-7920 | |
dc.identifier.journal | International Journal of Tuberculosis and Lung Disease | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2022-05-30 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2022-11-01 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2023-06-20T14:36:13Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2023-06-20T14:40:22Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2022-11-01 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2022 The Union. This article is Open Access under the terms of the Creative Commons CC BY licence.